Literature DB >> 9310247

A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients.

D C McMillan1, P O'Gorman, K C Fearon, C S McArdle.   

Abstract

Advanced gastrointestinal cancer patients with weight loss and an acute-phase response (n = 15) were given megestrol acetate (480 mg day(-1)) and ibuprofen (1200 mg day(-1)) for 6 weeks. Overall, there was an increase in body weight (P = 0.01) and a reduction in C-reactive protein concentrations (P = 0.02), with no change in total body water (P = 0.24) over this period. This regimen may be an effective non-toxic treatment for cancer cachexia and is worthy of further study.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9310247      PMCID： PMC2228041          DOI： 10.1038/bjc.1997.463

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  18 in total

Review 1.  The Sir David Cuthbertson Medal Lecture 1991. The mechanisms and treatment of weight loss in cancer.

Authors:  K C Fearon
Journal:  Proc Nutr Soc       Date:  1992-08       Impact factor: 6.297

2.  A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer.

Authors:  H L Parnes; J S Abrams; N S Tchekmedyian; N Tait; J Aisner
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

3.  Treatment of cancer anorexia with megestrol acetate: which is the optimal dose?

Authors:  J Feliu; M González-Barón; A Berrocal; A Ordóñez; J M Barón-Saura
Journal:  J Natl Cancer Inst       Date:  1991-03-20       Impact factor: 13.506

4.  Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss.

Authors:  T Preston; K C Fearon; D C McMillan; F P Winstanley; C Slater; A Shenkin; D C Carter
Journal:  Br J Surg       Date:  1995-02       Impact factor: 6.939

5.  Evaluation of multi-frequency bio-impedance analysis for the assessment of extracellular and total body water in surgical patients.

Authors:  W J Hannan; S J Cowen; K C Fearon; C E Plester; J S Falconer; R A Richardson
Journal:  Clin Sci (Lond)       Date:  1994-04       Impact factor: 6.124

Review 6.  Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein.

Authors:  M B Pepys; M L Baltz
Journal:  Adv Immunol       Date:  1983       Impact factor: 3.543

7.  Appetite stimulation with megestrol acetate in cachectic cancer patients.

Authors:  N S Tchekmedyian; N Tait; M Moody; F A Greco; J Aisner
Journal:  Semin Oncol       Date:  1986-12       Impact factor: 4.929

8.  Megestrol acetate in cancer anorexia and weight loss.

Authors:  N S Tchekmedyian; M Hickman; J Siau; F A Greco; J Keller; H Browder; J Aisner
Journal:  Cancer       Date:  1992-03-01       Impact factor: 6.860

9.  Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients.

Authors:  D C McMillan; E Leen; J Smith; C Sturgeon; T Preston; T G Cooke; C S McArdle
Journal:  Eur J Surg Oncol       Date:  1995-10       Impact factor: 4.424

10.  Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients.

Authors:  S J Wigmore; J S Falconer; C E Plester; J A Ross; J P Maingay; D C Carter; K C Fearon
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640
View more
  9 in total

Review 1.  Managing cancer-related anorexia/cachexia.

Authors:  G Mantovani; A Macciò; E Massa; C Madeddu
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  A review of the drug treatment of cachexia associated with cancer.

Authors:  B Gagnon; E Bruera
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

3.  Assessment of gastrointestinal function and response to megesterol acetate in subjects with gastrointestinal cancers and weight loss.

Authors:  John Deutsch; J Fred Kolhouse
Journal:  Support Care Cancer       Date:  2004-04-03       Impact factor: 3.603

4.  The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer.

Authors:  M D Barber; J A Ross; A C Voss; M J Tisdale; K C Fearon
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

5.  A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss.

Authors:  D C McMillan; S J Wigmore; K C Fearon; P O'Gorman; C E Wright; C S McArdle
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

6.  Associations of Prior Chronic Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Glucocorticoids With Cachexia Incidence and Survival.

Authors:  Santiago Olaechea; Anne Gilmore; Christian Alvarez; Bhavani S Gannavarapu; Rodney Infante; Puneeth Iyengar
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

7.  Cancer cachexia: impact, mechanisms and emerging treatments.

Authors:  Vanessa C Vaughan; Peter Martin; Paul A Lewandowski
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-10-25       Impact factor: 12.910

8.  Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study.

Authors:  F Fusun Bolukbas; Hasan Kilic; Cengiz Bolukbas; Mahmut Gumus; Mehmet Horoz; Nazim S Turhal; Birsel Kavakli
Journal:  BMC Cancer       Date:  2004-06-24       Impact factor: 4.430

Review 9.  Pancreatic cancer cachexia: a review of mechanisms and therapeutics.

Authors:  Carlyn R Tan; Patrick M Yaffee; Laith H Jamil; Simon K Lo; Nicholas Nissen; Stephen J Pandol; Richard Tuli; Andrew E Hendifar
Journal:  Front Physiol       Date:  2014-03-03       Impact factor: 4.566
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.